Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.

Abstract

Despite the benefit of statin therapy in the prevention of coronary heart disease, a considerable inter-individual variation exists in its response. It is well recognized that genetic variation can contribute to differences in drug disposition and, consequently, clinical efficacy at the population level. Pharmacogenetics, exploring genetic polymorphisms… (More)

Topics

Cite this paper

@article{Kajinami2004PharmacogeneticsOH, title={Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.}, author={Kouji Kajinami and Noboru Takekoshi and Margaret E. Brousseau and Ernst Sch{\"a}fer}, journal={Atherosclerosis}, year={2004}, volume={177 2}, pages={219-34} }